The nation of Zimbabwe has declined a significant American health deal worth 367 million US dollars (272 million pounds) spanning five years due to Washington's demand for sensitive biological samples.
This rejection came to light following a government memo from December was leaked, which showed Head of State Emmerson Mnangagwa deemed the deal was "skewed".
A government spokesperson later clarified that the US was seeking health data for scientific study and commercial gain but refused to share the benefits from any future vaccines.
"We will now turn to the difficult and regrettable task of ending our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy said the United States had provided more than $1.9bn in health funding to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has appealed for continued dialogue to reach a agreement suitable to both sides so the country's vital HIV treatment initiative can be sustained.
Broader Background
This rejection follows a comparable case in neighbouring Kenya, where a high court blocked a related health funding agreement after legal challenges were filed about the security of citizens' health data.
Since returning to office recently, US President Donald Trump has reduced foreign aid and closed the US Agency for International Development (USAID).
The agency had overseen aid for the US government, but Trump argued its expenditure was "inefficient" and his government was seeking government-to-government agreements to boost openness and accountability.
As per statements, 16 African countries have to date agreed to similar agreements, representing over $18.3bn in new funding.
Details of the Declined Agreement
The money for Zimbabwe would have supported "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this partnership would have delivered significant benefits for the people of Zimbabwe, especially the 1.2 million presently receiving HIV treatment via US-supported initiatives," the Ambassador said.
However, official spokesman Nick Mangwana argued the proposed deal was "asymmetrical".
"Zimbabwe was being asked to surrender its genetic material and health information indefinitely, with no corresponding promise of access to any medical innovations – such as vaccines, diagnostics, or treatments – that could result from that provided information," Mangwana explained.
"Effectively, our country would supply the basic resources for scientific discovery without any certainty that the resulting innovations would be available to our population if a new disease outbreak arise."
Sovereignty and Global Health
Mangwana further said that the US's withdrawal from the World Health Organization (WHO) and its pursuit of one-on-one health agreements were upending frameworks previously established via the global organization.
The spokesperson cited its Pathogen Access and Benefit Sharing scheme created to manage future pandemics.
"This system is intended to guarantee that when a nation contributes its samples, the resulting advantages – such as vaccines and treatments – are distributed fairly, not commercialised exclusively by those with the capability to develop them."
The government's concerns over the US deal "must not be interpreted as hostility towards the US," he added.
"We are open to further dialogue with our US partners on how subsequent co-operation could be designed in a manner that honours the independence and dignity of each country."
Medical Community Reaction
A leading public health body said it recognised the official position, but urged that negotiations should continue since a large portion of the nation's Aids initiatives relied on international support.
"In cases where technical issues arise, including those relating to information security or agreement terms, these can frequently be addressed through detailed discussion and mutually agreed protections," the group added.
The halted deal underscores the ongoing debate between accepting much-needed foreign assistance and safeguarding a country's data in an ever more data-driven world.